---
figid: PMC7760252__pharmaceuticals-13-00418-g003
figlink: pmc/articles/PMC7760252/figure/pharmaceuticals-13-00418-f003/
number: F3
caption: Overview of CDK4/6 and MAPK inhibitors. (a) FDA approved small-molecule inhibitors
  palbociclib, abemaciclib and ribociclib bind to CDK4/6 and prevent phosphorylation
  of Rb (indicated by the star symbol), which can result in cell cycle arrest in the
  G1 phase, block of differentiation and survival. (b) Inhibitors of the ERK pathway
  blocking the prosurvival and proliferative effects of ERK signaling. (c) Inhibitors
  of p38 are controversial and can have opposing effects as p38 is a tumor suppressor
  but can also have tumor promoting effects at later stages of cancer development.
  “T-lines” indicate inhibition, arrows indicate activation and dashed arrows indicate
  translocation into the nucleus. The arrows at the bottom of each panel show major
  outcomes of the signaling networks.
pmcid: PMC7760252
papertitle: CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment.
reftext: Lisa Scheiblecker, et al. Pharmaceuticals (Basel). 2020 Dec;13(12):418.
pmc_ranked_result_index: '3811'
pathway_score: 0.9555662
filename: pharmaceuticals-13-00418-g003.jpg
figtitle: CDK4/6 and MAPK inhibitors
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7760252__pharmaceuticals-13-00418-g003.html
  '@type': Dataset
  description: Overview of CDK4/6 and MAPK inhibitors. (a) FDA approved small-molecule
    inhibitors palbociclib, abemaciclib and ribociclib bind to CDK4/6 and prevent
    phosphorylation of Rb (indicated by the star symbol), which can result in cell
    cycle arrest in the G1 phase, block of differentiation and survival. (b) Inhibitors
    of the ERK pathway blocking the prosurvival and proliferative effects of ERK signaling.
    (c) Inhibitors of p38 are controversial and can have opposing effects as p38 is
    a tumor suppressor but can also have tumor promoting effects at later stages of
    cancer development. “T-lines” indicate inhibition, arrows indicate activation
    and dashed arrows indicate translocation into the nucleus. The arrows at the bottom
    of each panel show major outcomes of the signaling networks.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HRAS
  - KRAS
  - NRAS
  - CYCS
  - CDK4
  - CDK6
  - MAP3K5
  - ARAF
  - BRAF
  - RAF1
  - NR2C2
  - MAP3K1
  - E2F3
  - E2F8
  - E2F1
  - E2F2
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - MAP2K1
  - MAP2K2
  - MAP2K3
  - MAP2K6
  - MAPK3
  - MAPK1
  - MAPK14
  - MAPK11
  - MAPK13
  - MAPK12
  - Sorafenib
  - Vemurafenib
  - Encorafenib
  - Dabrafenib
  - Trametinib
  - Binimetinib
  - Selumetinib
  - Cobimetinib
  - Ralimetinib
  - GDC-0994
  - tumor
genes:
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Cyc
  symbol: CYC
  source: hgnc_alias_symbol
  hgnc_symbol: CYCS
  entrez: '54205'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: ASK1
  symbol: ASK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP3K5
  entrez: '4217'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: TAK1
  symbol: TAK1
  source: hgnc_alias_symbol
  hgnc_symbol: NR2C2
  entrez: '7182'
- word: (MEKK
  symbol: MEKK
  source: hgnc_alias_symbol
  hgnc_symbol: MAP3K1
  entrez: '4214'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MKK3
  symbol: MKK3
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K3
  entrez: '5606'
- word: MKK6
  symbol: MKK6
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K6
  entrez: '5608'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: р38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: р38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: р38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: р38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
chemicals:
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Encorafenib
  source: ''
  identifier: ''
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Binimetinib
  source: MESH
  identifier: C581313
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Ralimetinib
  source: ''
  identifier: ''
- word: GDC-0994
  source: MESH
  identifier: C044932
diseases:
- word: tumor
  source: MESH
  identifier: D009369
figid_alias: PMC7760252__F3
redirect_from: /figures/PMC7760252__F3
figtype: Figure
---
